Inhibrx Biosciences, Inc. (INBX) - Dilution Analysis

Visualizing historical and potential share dilution over time

Dilution Analysis

Medium Risk
Moderate dilution risk
Last updated: May 14, 2026

Risk Assessment Details

Potential Dilution: 0.0% of current shares
Recent Dilution: 11.06% (2 years)
Historical Dilution Factor: moderate recent dilution
Outstanding Shares
16M
Potential Supply
0
Additional shares possible
Splits
None
Past 2 years

Summary

INBX currently has 15.6M outstanding shares. with minimal authorized share overhang for future dilution. The company has diluted shareholders by 11.06% over the past 2 years through share issuances.

Share Structure Timeline

Outstanding Shares
Total Supply

Historical Data Points

Date Event Outstanding Supply
May 14, 2026

10-Q filing | 15.6M shares outstanding

16M 0
Mar 19, 2026

10-K filing | 15.5M shares outstanding

15M 0
Aug 13, 2025

10-Q filing | 15.5M shares outstanding

15M 0
Jun 02, 2025

POS AM filing: This POS AM filing relates to an offering of up to 2,449,921 shares of Common Stock by selling stockholders, including shares underlying warrants, with the company not receiving any proceeds from the sale of securities, except for potential proceeds from warrant exercises.

15M 0
May 14, 2025

10-Q filing | 15.5M shares outstanding

15M 0
Apr 17, 2025

POS AM filing: This POS AM filing relates to the proposed resale of up to 2,449,921 shares of Inhibrx Biosciences, Inc. common stock by selling stockholders.

15M 0
Mar 17, 2025

10-K filing | 14.8M shares outstanding

15M 2.4M
Jan 13, 2025

8-K filing: Inhibrx Biosciences, Inc. entered into a Loan and Security Agreement with Oxford Finance LLC, providing for a term loan facility of up to $150.0 million, and issued warrants to purchase 140,741 shares of common stock at an exercise price of $14.21 per share in connection with the initial tranche of funding.

15M 2.4M
Nov 14, 2024

10-Q filing | 15.5M shares outstanding

15M 2.4M
Aug 13, 2024

10-Q filing | 14.6M shares outstanding

15M 2.4M
Jun 11, 2024

S-1 filing: This S-1 filing relates to the proposed resale of up to 2,449,921 shares of common stock by selling stockholders, including shares underlying warrants.

N/A 2.4M
May 30, 2024

8-K filing: Inhibrx Biosciences, Inc. completed the distribution of its common stock to holders of Inhibrx, Inc.'s common stock, issued warrants to purchase up to 991,849 shares of common stock, issued 1,838 shares of common stock to Oxford Finance LLC, filed an Amended & Restated Certificate of Incorporation, and adopted the Amended & Restated Bylaws.

N/A 0
Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam Unsubscribe anytime